Keywords: schering, ag, completes, benefit, ph, iii, study

Schering AG completes BENEFIT Ph III study in MS

Article | 27 June 2005

Print This

German drugmaker Schering AG says that the last of 468 patients has completed two-year treatment with Betaferon (interferon beta-1a) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in